Goodwin Procter·PHARMA / BIOTECH
Teva and Samsung Bioepis Expand Deal to Six Biosimilar Candidates
Teva and Samsung Bioepis announced a global license, development and commercialization agreement covering up to six potential biosimilar candidates, widening an existing biosimilar partnership.
tevasamsung-bioepisbiosimilarslicensingbiopharma-business-development
Read the original firm alert → Wednesday, October 21, 2026